Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab utilization and impact in ulcerative colitis (UK, Phase 4)
2013-004583-56Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in autoimmune colitis, sponsored by Merck & Co. Started Dec 2013; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-004583-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004583-56.